Thompson Street Capital Partners (TSCP) has invested in Sabai Global, a provider of biosafety consulting services.
Sabai operates through three subsidiaries – Clinical Biosafety Services, Castle IRB, and Shield Consulting – and provides regulatory review and biosafety consulting services to pharmaceutical sponsors, contract research organizations, academic health systems and clinical research site networks. The company’s complementary services are used to facilitate regulatory approval and accelerate clinical research timelines for drug development.
Sabai, founded in 2017, is led by CEO Chris Jenkins and is headquartered near St. Louis in Chesterfield, Missouri.
“Clinical Research and specifically the unique regulatory elements of biosafety and human research protections are all around expertise and people. Conducting clinical research in the areas of oncology, rare disease and infectious disease as our primary indications, requires talented colleagues, a shared vision, and a deep knowledge of the life sciences industry,” said Mr. Jenkins. “We chose TSCP as our partner to continue our growth in supporting these exciting therapeutic areas, especially in cell and gene therapy, because of their past, present, and future focus in supporting the life sciences companies they invest in, which now include Sabai.”
“Our team has worked hard to identify an asset that serves the rapidly growing cell and gene therapy market and was extremely pleased to find one led by a CEO as passionate as Chris in the St. Louis area,” said Matt Scherrer, a managing director at TSCP. “We are proud to support Sabai’s continued growth as they help bring the most cutting-edge, life-saving treatments to market in an efficient, safe, and ethical manner.”
St. Louis-based TSCP makes equity investments of $50 million to $250 million in companies with EBITDA between $5 million and $50 million. Sectors of interest include healthcare and life science services, software and technology services, and business and consumer products and services.
“As a founder-owned and operated business in the life sciences sector, Sabai represents an excellent fit for the TSCP portfolio” said John Kane, a Sabai board member and TSCP executive advisor. “I’m looking forward to working closely with Chris and his team as they expand Sabai’s leading suite of biosafety, ethical, and regulatory review solutions.”
In August 2022, TSCP closed its oversubscribed sixth investment fund, Thompson Street Capital Partners VI LP, with total commitments exceeding its $1.5 billion target. TSCP’s earlier fund closed in July 2018 at its hard cap of $1.15 billion.
© 2023 Private Equity Professional | February 9, 2023
